{"title":"听力康复中的药理学问题。","authors":"Philip A Bird, Michael J Bergin","doi":"10.1159/000485541","DOIUrl":null,"url":null,"abstract":"<p><p>Surgery aimed at hearing rehabilitation risks damaging residual inner ear function, especially cochlear implant surgery. Pharmacological intervention to reduce this risk has shown great promise in animal models. The challenge is to deliver medication to the appropriate part of the inner ear in appropriate concentrations for long enough to be effective. Barriers to achieving these goals include: the blood/labyrinth barrier, limiting systemic drug delivery to the inner ear, slow rates of diffusion from the base of the cochlea to the apex, limiting intratympanic delivery from the middle ear to the cochlear apex, delayed intracochlear fibrosis, requiring extended medication delivery postoperatively. Intracochlear drug delivery via a drug-eluting cochlear implantation (CI) electrode may solve many of these pharmacologic issues. It is likely that more than one medication will be necessary to maximize inner ear protection and this may include steroids and appropriate growth factors. Such protection may also be helpful for otologic surgical procedures other than CI that have lower risks to hearing.</p>","PeriodicalId":39848,"journal":{"name":"Advances in Oto-Rhino-Laryngology","volume":"81 ","pages":"114-122"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000485541","citationCount":"3","resultStr":"{\"title\":\"Pharmacological Issues in Hearing Rehabilitation.\",\"authors\":\"Philip A Bird, Michael J Bergin\",\"doi\":\"10.1159/000485541\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Surgery aimed at hearing rehabilitation risks damaging residual inner ear function, especially cochlear implant surgery. Pharmacological intervention to reduce this risk has shown great promise in animal models. The challenge is to deliver medication to the appropriate part of the inner ear in appropriate concentrations for long enough to be effective. Barriers to achieving these goals include: the blood/labyrinth barrier, limiting systemic drug delivery to the inner ear, slow rates of diffusion from the base of the cochlea to the apex, limiting intratympanic delivery from the middle ear to the cochlear apex, delayed intracochlear fibrosis, requiring extended medication delivery postoperatively. Intracochlear drug delivery via a drug-eluting cochlear implantation (CI) electrode may solve many of these pharmacologic issues. It is likely that more than one medication will be necessary to maximize inner ear protection and this may include steroids and appropriate growth factors. Such protection may also be helpful for otologic surgical procedures other than CI that have lower risks to hearing.</p>\",\"PeriodicalId\":39848,\"journal\":{\"name\":\"Advances in Oto-Rhino-Laryngology\",\"volume\":\"81 \",\"pages\":\"114-122\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000485541\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Oto-Rhino-Laryngology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000485541\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/4/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Oto-Rhino-Laryngology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000485541","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/4/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Surgery aimed at hearing rehabilitation risks damaging residual inner ear function, especially cochlear implant surgery. Pharmacological intervention to reduce this risk has shown great promise in animal models. The challenge is to deliver medication to the appropriate part of the inner ear in appropriate concentrations for long enough to be effective. Barriers to achieving these goals include: the blood/labyrinth barrier, limiting systemic drug delivery to the inner ear, slow rates of diffusion from the base of the cochlea to the apex, limiting intratympanic delivery from the middle ear to the cochlear apex, delayed intracochlear fibrosis, requiring extended medication delivery postoperatively. Intracochlear drug delivery via a drug-eluting cochlear implantation (CI) electrode may solve many of these pharmacologic issues. It is likely that more than one medication will be necessary to maximize inner ear protection and this may include steroids and appropriate growth factors. Such protection may also be helpful for otologic surgical procedures other than CI that have lower risks to hearing.
期刊介绍:
Material for each volume in this series has been skillfully selected to document the most active areas of otorhinolaryngology and related specialties, such as neuro-otology and oncology. The series reproduces results from basic research and clinical studies pertaining to the pathophysiology, diagnosis, clinical symptoms, course, prognosis and therapy of a variety of ear, nose and throat disorders. The numerous papers correlating basic research findings and clinical applications are of immense value to all specialists engaged in the ongoing efforts to improve management of these disorders. Acting as a voice for its field, the series has also been instrumental in developing subspecialities into established specialities.